
Napp Pharmaceuticals has launched its own biosimilar version of an anti-TNF biologic in Europe paving the way for patient access …
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

